Table 2.

Mean (± SD) amplitudes [μV] of target ERP subcomponents MMN and N2b.

	BCAA	Placebo	F	p	η 2
MMN at Fz	−3.56 ± 3.80	−4.91 ± 2.64	1.40	.250	.075
MMN at FCz	−3.48 ± 3.55	−4.72 ± 2.88	1.82	.192	.083
MMN at Cz	−3.33 ± 2.74	−4.19 ± 3.35	1.63	.217	.066
MMN at Pz	−2.02 ± 2.72	−3.83 ± 2.92	2.82	.117	.119
N2b at Fz	−3.29 ± 3.84	−5.17 ± 4.26	4.16	.055	.172
N2b at FCz	−4.16 ± 3.70	−6.57 ± 4.22	9.04	.0069	.311
N2b at Cz	−4.70 ± 3.92	−6.44 ± 4.49	4.89	.039	.197
N2b at Pz	−3.94 ± 4.06	−3.96 ± 3.53	0.03	.867	.001

Significant differences (p<.01) are highlighted; BCAA, branched chain amino acid; MMN, mismatch negativity; η², partial eta-squared.